ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
hepa82
|
48 |
14K |
2 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
hepa82
|
48 |
14K |
1 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
hepa82
|
48 |
14K |
0 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
14K
|
0
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
6 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
45
|
12K
|
6
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
6 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
45
|
12K
|
6
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
8 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
45
|
12K
|
8
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
1 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
49
|
14K
|
1
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
0 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
49
|
14K
|
0
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
0 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
49
|
14K
|
0
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
4 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
45
|
12K
|
4
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
4 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
45
|
12K
|
4
|
|
ASX - By Stock
|
APX |
Re:
APX Charts
|
|
hepa82
|
1.0K |
335K |
0 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.0K
|
335K
|
0
|
|
ASX - By Stock
|
APX |
Re:
APX Charts
|
|
hepa82
|
1.0K |
335K |
1 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.0K
|
335K
|
1
|
|
ASX - By Stock
|
G1A |
Re:
Ann: Appointment of Voluntary Administrators
|
|
hepa82
|
51 |
31K |
9 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
51
|
31K
|
9
|
|
ASX - By Stock
|
TNC |
Re:
Ann: TNC announces $5M institutional placement
|
|
hepa82
|
60 |
24K |
2 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
60
|
24K
|
2
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
6 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
45
|
12K
|
6
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
12K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
45
|
12K
|
4
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Acquisition of TrialsWest Group
|
|
hepa82
|
2 |
944 |
8 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
2
|
944
|
8
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
3 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
49
|
14K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
49
|
14K
|
0
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Collaboration with Micron, Inc.
|
|
hepa82
|
10 |
2.0K |
2 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
10
|
2.0K
|
2
|
|
ASX - By Stock
|
OPL |
Re:
Ann: Opyl receives non-binding offer for its Opin business
|
|
hepa82
|
14 |
3.4K |
2 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
14
|
3.4K
|
2
|
|
ASX - By Stock
|
OPL |
Re:
Ann: Opyl receives non-binding offer for its Opin business
|
|
hepa82
|
14 |
3.4K |
3 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
14
|
3.4K
|
3
|
|
ASX - By Stock
|
AMD |
Re:
AMD General Discussion
|
|
hepa82
|
335 |
138K |
2 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
335
|
138K
|
2
|
|
ASX - By Stock
|
AMD |
Re:
AMD General Discussion
|
|
hepa82
|
335 |
138K |
4 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
335
|
138K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix to Present at Euroz Hartley Institutional Conference
|
|
hepa82
|
37 |
9.5K |
12 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
37
|
9.5K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
hepa82
|
247 |
76K |
0 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
76K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
hepa82
|
247 |
76K |
21 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
76K
|
21
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
hepa82
|
247 |
76K |
11 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
76K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
159
|
50K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
20 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
20
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
11 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
7 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
12 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
19 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
159
|
50K
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
7 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
159
|
50K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
50K |
19 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
159
|
50K
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
hepa82
|
640 |
207K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
640
|
207K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Interim Analyses of Clinical Trials
|
|
hepa82
|
185 |
48K |
9 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
185
|
48K
|
9
|
|
ASX - By Stock
|
ODE |
Re:
Ann: TARGETS GENERATED AT GASCOYNE EAST PROJECT
|
|
hepa82
|
10 |
3.3K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10
|
3.3K
|
5
|
|
ASX - By Stock
|
VMM |
Re:
Ann: Viridis Completes A$4.5 Million Placement
|
|
hepa82
|
239 |
52K |
2 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
239
|
52K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
100K |
37 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
100K
|
37
|
|
ASX - By Stock
|
VMM |
Re:
Ann: Viridis Completes A$4.5 Million Placement
|
|
hepa82
|
239 |
52K |
0 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
239
|
52K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
100K |
9 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
100K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
100K |
5 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
100K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
100K |
4 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
100K
|
4
|
|
ASX - By Stock
|
VMM |
Re:
Ann: Viridis Completes A$4.5 Million Placement
|
|
hepa82
|
239 |
52K |
0 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
239
|
52K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
hepa82
|
9.5K |
2.8M |
6 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
9.5K
|
2.8M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
100K |
23 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
100K
|
23
|
|
ASX - By Stock
|
EVN |
Re:
Ann: Annual Mineral Resource and Ore Reserves Statement
|
|
hepa82
|
2 |
1.1K |
6 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
2
|
1.1K
|
6
|
|